258 related articles for article (PubMed ID: 27108678)
1. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
Liu D; Ma X; Liu Y; Zhou H; Shi C; Wu F; Jiang J; Hu P
Eur J Pharm Sci; 2016 Jun; 89():73-82. PubMed ID: 27108678
[TBL] [Abstract][Full Text] [Related]
2. Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
Gilibili RR; Bhamidipati RK; Mullangi R; Srinivas NR
J Pharm Pharm Sci; 2015; 18(3):434-48. PubMed ID: 26517136
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J
Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.
Liu X; Liu Y; Liu H; Li H; Yang J; Hu P; Xiao X; Liu D
Front Endocrinol (Lausanne); 2021; 12():694390. PubMed ID: 34616361
[TBL] [Abstract][Full Text] [Related]
6. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
[TBL] [Abstract][Full Text] [Related]
7. Metabolites characterization of a novel DPP-4 inhibitor, imigliptin in humans and rats using ultra-high performance liquid chromatography coupled with synapt high-resolution mass spectrometry.
Liu Y; Yao X; Song L; Liu H; Zhao Q; Jiang J; Ni G; Shi C; Ma X; Zhou H; Liu D; Hu P
J Pharm Biomed Anal; 2018 Aug; 157():189-200. PubMed ID: 29803910
[TBL] [Abstract][Full Text] [Related]
8. A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study.
Liu Y; Song L; Yao X; Wu Y; Liu H; Zhao Q; Jiang J; Shi C; Ma X; Zhou H; Liu D; Hu P
Biomed Chromatogr; 2018 Nov; 32(11):e4324. PubMed ID: 29952007
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
[TBL] [Abstract][Full Text] [Related]
10. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of KR-66223, a novel DPP-4 inhibitor.
Song JS; Lee KR; Kwon HJ; Rhee SD; Kim MS; Choi SH; Lee SH; Song IS; Ahn JH; Ahn SH; Bae MA
Drug Metab Pharmacokinet; 2012; 27(2):216-22. PubMed ID: 22240842
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males.
Sangle GV; Patil M; Deshmukh NJ; Shengule SA; Kamble S; Vuppalavanchu KK; Kale S; Baig MLA; Singh G; Shaikh J; Tripathi J; Aravindababu P
Eur J Clin Pharmacol; 2018 May; 74(5):561-569. PubMed ID: 29511780
[TBL] [Abstract][Full Text] [Related]
13. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
Agrawal R; Bahare RS; Jain P; Dikshit SN; Ganguly S
Mini Rev Med Chem; 2012 Nov; 12(13):1345-58. PubMed ID: 22512582
[TBL] [Abstract][Full Text] [Related]
14. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.
Grimshaw CE; Jennings A; Kamran R; Ueno H; Nishigaki N; Kosaka T; Tani A; Sano H; Kinugawa Y; Koumura E; Shi L; Takeuchi K
PLoS One; 2016; 11(6):e0157509. PubMed ID: 27328054
[TBL] [Abstract][Full Text] [Related]
15. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
16. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Chaykovska L; von Websky K; Rahnenführer J; Alter M; Heiden S; Fuchs H; Runge F; Klein T; Hocher B
PLoS One; 2011; 6(11):e27861. PubMed ID: 22125632
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP).
Choi S; Han S; Jeon S; Yim DS
Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31311144
[TBL] [Abstract][Full Text] [Related]
18. Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model.
Patel H; Joharapurkar AA; Bahekar R; Patel P; Kshirsagar SG; Modi N; Ghoghari A; Patel VJ; Jain MR; Srinivas NR; Patel PR; Desai RC
Drug Res (Stuttg); 2017 Apr; 67(4):223-227. PubMed ID: 28158894
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
20. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
